Evidence map›Paper›PMID 42181160›Full record

ArticleClinical and translational radiation oncology2026

Chronotype-based radiotherapy in localised prostate cancer: protocol for a prospective cohort integrating MCTQ and salivary DLMO.

Rúben Oliveira-Sousa, Íris R Carriço, Catarina Macedo-Silva, Bárbara Barbosa, Ana Ferreira, Catarina Ribeiro, João Santos, Carla Castro, Carmen Jerónimo, Vera Miranda-Gonçalves

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rúben Oliveira-SousaCancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPO Porto), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Íris R CarriçoCancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPO Porto), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Catarina Macedo-SilvaCancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPO Porto), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Bárbara BarbosaMedical Physics, Radiobiology & Radiation Protection Group, IPO Porto Research Center (CI-IPO Porto), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Ana FerreiraPorto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Porto, Portugal.
Catarina RibeiroPorto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Porto, Portugal.
João SantosMedical Physics, Radiobiology & Radiation Protection Group, IPO Porto Research Center (CI-IPO Porto), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Carla CastroPorto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Porto, Portugal.
Carmen JerónimoCancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPO Porto), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
Vera Miranda-GonçalvesCancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPO Porto), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a prospective observational cohort protocol evaluating whether chronotype-based radiotherapy timing reduces treatment-related toxicities in localised prostate cancer. Individual circadian phase is characterised using the Munich ChronoType Questionnaire and salivary dim-light melatonin onset. The primary endpoint is late genitourinary toxicity grade ≥2 at 12 months, with secondary endpoints including gastrointestinal toxicity and patient-reported outcomes. The protocol is conducted at IPO Porto and designed for multi-site adoption.

Identifiers

PMID42181160
PMCPMC13197716

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.